Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment

Jürgen K. Rockstroh

Department of Medicine I, University Hospital Bonn, Bonn, Germany

Moti N. Ramgopal

Midway Immunology and Research Center, Fort Pierce, FL

Adrian Curran Fàbregas

Department of Infectious Diseases, Vall d’Hebron University Hospital, Barcelona

Malcolm Hedgcock

Spectrum Health, Vancouver, BC, Canada

Kimberly A. Workowski

Department of Medicine, Emory University, Atlanta

Sylvie Ronot-Bregigeon

Hôpital Sainte-Marguerite, Aix-Marseille Université, Assistance Publique–Hôpitaux de Marseille, Marseille, France

Isabel Cassetti

Cynthia Brinson

Central Texas Clinical Research, Austin

Samir K. Gupta

Indiana University School of Medicine, Indianapolis

Chien-Ching Hung

Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin

Mark O’Reilly

East Sydney Doctors, Darlinghurst, NSW, Australia

Jihad Slim

New York Medical College, Valhalla

Hiroyuki Gatanaga

Japan Institute for Health Security, National Center for Global Health and Medicine, Tokyo

Peter Shalit

Peter Shalit MD and Associates, Seattle

Shan-Yu Liu

Gilead Sciences, Foster City, CA

Stephanie O. Klopfer

Merck, Rahway, NJ

Fadi Shihadeh

Gilead Sciences, Foster City, CA

Nidhi Patel

Merck, Rahway, NJ

Reneé-Claude Mercier

Gilead Sciences, Foster City, CA

Melissa Shaughnessy

Merck, Rahway, NJ

Hadas Dvory-Sobol

Gilead Sciences, Foster City, CA

Devi SenGupta

Gilead Sciences, Foster City, CA

Cyril Llamoso

Merck, Rahway, NJ

Martin S. Rhee

Gilead Sciences, Foster City, CA

Chloe Orkin

SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London